Navigation Links
Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/4/2009

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that the company will be presenting at the upcoming 11th Annual BIO CEO & Investor Conference at 11:30 a.m. Eastern Time on February 10, 2009 at the Waldorf-Astoria Hotel in New York City, NY.

The live webcast of this presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing voreloxin in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... solutions for clinical development reported today that it is launching two new additions ... company will be demonstrating new capabilities at the DIA 2017 Annual Meeting in ...
(Date:6/16/2017)... (PRWEB) , ... June 16, 2017 , ... CTNext ... Entrepreneur Innovation Awards (EIA), held at The LOFT at Chelsea Piers in Stamford. , ... ideas to a panel of judges for an opportunity to secure $10,000 awards to ...
(Date:6/15/2017)... ... June 15, 2017 , ... DuPont ... Biofuels, will be speaking at Bloomberg’s 2017 Sustainable Business Summit: Seattle ... environmental and sustainability officials on a panel titled “Developing a Corporate Renewables Strategy.” ...
Breaking Biology Technology:
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):